Eveliqure Biotechnologies GmbH
Eveliqure Biotechnologies is an innovative biotech company developing novel vaccines for the prevention of diarrhoeal diseases, targeting both travelers and populations in endemic regions of low- and middle-income countries. The company has developed a live attenuated vaccine platform based on genetically modified Shigella strains, aiming to induce broad protection against multiple pathogens, including Shigella and ETEC. Eveliqure's mission is to improve global health through innovative vaccine solutions, with a focus on diarrhoeal diseases that cause significant morbidity and mortality worldwide.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Orally administered live attenuated vaccine candidate for Shigella and ETEC
A live attenuated Shigella‑based vaccine candidate engineered for serotype‑independent protection by removal of the LPS O‑antigen, inactivation of invasion systems and enterotoxin, and stabilized to retain heterologous antigen expression; designed to express ETEC antigen(s) including a fusion toxoid to elicit neutralizing antibodies and induce mucosal immunity following oral administration.
Orally administered live attenuated vaccine candidate for Shigella and ETEC
A live attenuated Shigella‑based vaccine candidate engineered for serotype‑independent protection by removal of the LPS O‑antigen, inactivation of invasion systems and enterotoxin, and stabilized to retain heterologous antigen expression; designed to express ETEC antigen(s) including a fusion toxoid to elicit neutralizing antibodies and induce mucosal immunity following oral administration.
Services
Participation and management of multi‑partner research consortia to develop, manufacture and test clinical trial material and to run early clinical studies funded by public grants and contracts.
Participation and management of multi‑partner research consortia to develop, manufacture and test clinical trial material and to run early clinical studies funded by public grants and contracts.
Expertise Areas
- Live attenuated bacterial vaccine development
- Heterologous antigen design and expression
- Mucosal immunology and oral vaccine development
- Preclinical immunogenicity and safety testing
Key Technologies
- Live attenuated bacterial vaccine platform
- Targeted genetic attenuation (gene deletions/inactivation)
- Genetic stabilization via gene transposition
- Heterologous antigen and fusion toxoid expression
News & Updates
Eveliqure has started clinical trials in Bangladesh for its vaccine candidate targeting Shigellosis and ETEC.
Positive results from Phase I clinical trials of Eveliqure's vaccine candidate.
Preclinical data supporting Eveliqure's vaccine candidate.
Start of Phase 1 clinical trial for Eveliqure's vaccine.
Funding secured from NIAID for Phase 2 clinical trials.
Additional private funding received.
Eveliqure has started clinical trials in Bangladesh for its vaccine candidate targeting Shigellosis and ETEC.
Positive results from Phase I clinical trials of Eveliqure's vaccine candidate.
Preclinical data supporting Eveliqure's vaccine candidate.
Start of Phase 1 clinical trial for Eveliqure's vaccine.
Funding secured from NIAID for Phase 2 clinical trials.
Additional private funding received.